The global Smart Insulin Pens Market was valued at $877.26 million in 2024 and is projected to reach $1818.89 million by 2032, growing at a CAGR of 9.57%. The U.S. market accounted for 34% of global revenue in 2024 and is expected to reach $620.78 million by 2032, driven by rising diabetes prevalence and technology integration.

The growth of smart insulin pens is supported by expanding home healthcare trends, strong reimbursement programs, and collaborations between medical device manufacturers, digital health companies, and pharmaceutical leaders. Major players in the market include Medtronic, Novo Nordisk, and Eli Lilly and Company, among others.

In 2024, the Bluetooth segment held over 73% of the revenue share in the smart insulin pens market, offering real-time insulin dose tracking and data exchange with healthcare providers. The type 1 diabetes segment dominated the market, while hospital pharmacies led in distribution channels. North America accounted for 42% of market revenue in 2024.

Recent developments in the market include Ypsomed receiving FDA clearance for SmartPilot in 2025 and Medtronic receiving FDA clearance for a new InPen™ app in 2024. The Smart Insulin Pens Market Report provides insights on regulatory metrics, manufacturing details, technological adoption rates, patient outcomes, and reimbursement landscapes.

SNS Insider is a leading market research and consulting agency providing clients with current and accurate market data to make informed decisions. They offer surveys, video talks, and focus groups globally to deliver consumer insights and opinions for confident decision-making in changing circumstances.

Read more at GlobeNewswire: Smart Insulin Pens Market Size to be Worth $1818.89 Million